Blog
Gastrointestinal tumor markers: how to detect cancer risks before symptoms appear
What are tumor markers and what role do they play in diagnosis?
Tumor markers — are specific proteins, glycoproteins or enzymes that are produced by tumor cells or the body in response to a malignant formation. They can be present in the blood, urine, pleural or abdominal fluid and signal the possible presence of an oncological process. In particular, gastrointestinal (GI) tumor markers help doctors detect pathologies of the stomach, intestines, liver, and pancreas at preclinical stages.
These tests are not completely specific—tumor marker levels can also be elevated in benign conditions. However, they are indispensable for:
primary diagnosis of cancer in risk groups
assessment of treatment effectiveness (surgery, chemotherapy or radiotherapy)
early detection of relapse after remission
monitoring disease progression
What tumor markers are studied in gastrointestinal diseases?
| Tumor marker | Full name | The main pathologies associated with | Reference value* |
|---|---|---|---|
| CEA | Carcinoembryonic antigen | Cancer of the colon and rectum, stomach, pancreas, lungs | < 5 ng/ml |
| CA 19-9 | Carbohydrate antigen 19-9 | Cancer of the pancreas, bile ducts, stomach | < 37 U/ml |
| CA 72-4 | Mucin-like glycoprotein | Cancer of the stomach, gastrointestinal junction | < 6.9 U/ml |
| AFP | Alpha-fetoprotein | Primary liver cancer, hepatoma | < 10 ng/ml |
| CA 125 | High molecular weight antigen | Peritoneal involvement in gastrointestinal cancer | < 35 U/ml |
| CYFRA 21-1 | Cytokeratin 19 fragment | Cancer of the esophagus, stomach | < 3.3 ng/ml |
| TPS | Tissue polypeptide antigen | Stomach and intestinal cancer | < 80 U/L |
*Reference values may vary depending on the laboratory
Who is prescribed gastrointestinal tumor marker testing?
Patients with suspicious symptoms: persistent abdominal pain, weight loss, stool changes, bleeding, food aversion
People with a hereditary predisposition to oncological pathologies
Patients who have completed treatment for gastrointestinal cancer — to detect recurrences
In case of unclear diagnostic data - as part of differential diagnosis
To assess response to treatment (for example, if the marker decreases after chemotherapy, the therapy is effective)
Features of tumor markers: advantages and limitations
Advantages:
Non-invasive: the study is performed with a venous blood sample
Monitoring capability: dynamic level changes have diagnostic value
Execution speed
Indicator of recurrence before clinical manifestations appear
Limitation:
Are not specific - may increase with inflammation or benign tumors
Interpretation is only required in combination with other methods (CT, ultrasound, biopsy)
Not recommended for initial screening of healthy individuals
The World Health Organization emphasizes that tumor markers should only be used as a part of comprehensive diagnostics (WHO Guidelines).
An example of the use of tumor markers in practice
A patient with suspected pancreatic cancer has an elevated CA 19-9 level. After surgery and chemotherapy, the marker returns to normal. Six months later, the marker increases again — a CT scan is performed, revealing metastasis. Thanks to early detection, it is possible to continue effective treatment.
A 45-year-old woman is undergoing a preventive check-up, and her AFP level is elevated. Additional examinations are prescribed - liver ultrasound, MRI. She is diagnosed with hepatocarcinoma at an early stage, which allows avoiding metastases.
How to prepare for the analysis
The sample is taken on an empty stomach, at least 8 hours after the last meal.
For 24 hours - give up alcohol, physical and emotional overload
If possible, stop taking certain medications (in consultation with your doctor)
Before the test, rest for 10–15 minutes in a calm state.
Gastrointestinal tumor markers are an effective, affordable, and quick way to get additional information about the body's condition. When used correctly, they allow doctors to act proactively, reducing mortality and improving patient prognosis. If you are at risk, discuss the feasibility of such a test with a specialist.
